-+ 0.00%
-+ 0.00%
-+ 0.00%
12 Health Care Stocks Moving In Thursday's After-Market Session
Share
Listen to the news

Gainers

  • Revelation Biosciences (NASDAQ:REVB) shares moved upwards by 15.6% to $0.99 during Thursday's after-market session. The company's market cap stands at $4.9 million.
  • Vyome Holdings (NASDAQ:HIND) stock increased by 6.06% to $3.15. The market value of their outstanding shares is at $15.1 million.
  • Reviva Pharmaceuticals (NASDAQ:RVPH) shares increased by 3.98% to $0.35. The company's market cap stands at $38.2 million.
  • Xilio Therapeutics (NASDAQ:XLO) stock moved upwards by 3.66% to $0.64. The market value of their outstanding shares is at $40.3 million.
  • HCW Biologics (NASDAQ:HCWB) stock rose 3.59% to $1.44. The company's market cap stands at $4.3 million.
  • Apimeds Pharmaceuticals (AMEX:APUS) shares moved upwards by 2.89% to $2.13. The company's market cap stands at $22.7 million.

Losers

  • IO Biotech (NASDAQ:IOBT) shares decreased by 4.4% to $0.46 during Thursday's after-market session. The market value of their outstanding shares is at $14.9 million.
  • PharmaCyte Biotech (NASDAQ:PMCB) shares declined by 4.34% to $0.86. The company's market cap stands at $8.8 million.
  • Lexicon Pharmaceuticals (NASDAQ:LXRX) stock fell 2.28% to $1.72. The company's market cap stands at $566.9 million.
  • Cue Biopharma (NASDAQ:CUE) stock fell 2.25% to $0.36. The company's market cap stands at $34.2 million.
  • Healthcare Triangle (NASDAQ:HCTI) shares fell 2.2% to $0.36. The market value of their outstanding shares is at $4.3 million.
  • Regencell Bioscience (NASDAQ:RGC) stock fell 2.18% to $30.1. The company's market cap stands at $10.8 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending